{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:08:38Z","timestamp":1753182518754,"version":"3.37.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022.07037.CEECIND","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00211\/2020","UIDB\/00211\/2020"],"award-info":[{"award-number":["2022.07037.CEECIND","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00100\/2020","UIDB\/00211\/2020","UIDB\/00211\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The escalating antimicrobial resistance crisis urges the development of new antibacterial treatments with innovative mechanisms of action, particularly against the critical priority carbapenem-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (CRAB), <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (CRPA) and <jats:italic>Enterobacteriaceae<\/jats:italic> (CRE). Membrane-disrupting dodecyl deoxyglycosides have been reported for their interesting phosphatidylethanolamine-associated bactericidal activity against Gram-positive strains; however, their inability to penetrate the Gram-negative outer membrane (OM) renders them useless against the most challenging pathogens. Aiming to repurpose alkyl deoxyglycosides against Gram-negative bacteria, this study investigates the antimicrobial effects of five reference compounds with different deoxygenation patterns or anomeric configurations in combination with polymyxins as adjuvants for enhanced OM permeability. The generation of the lead 4,6-dideoxy scaffold was optimized through a simultaneous dideoxygenation step and applied to the synthesis of a novel alkyl 4,6-dideoxy <jats:italic>C<\/jats:italic>-glycoside <jats:bold>5<\/jats:bold>, herein reported for the first time. When combined with subtherapeutic colistin concentrations, most glycosides demonstrated potent antimicrobial activity against several multidrug-resistant clinical isolates of CRAB, CRE and CRPA exhibiting distinct carbapenem resistance mechanisms, together with acceptable cytotoxicity against human HEK-293T and Caco-2 cells. The novel 4,6-dideoxy <jats:italic>C<\/jats:italic>-glycoside <jats:bold>5<\/jats:bold> emerged as the most promising prototype structure for further development (MIC 3.1\u00a0\u03bcg\/mL when combined with colistin 0.5\u00a0\u03bcg\/mL against CRPA or 0.25\u00a0\u03bcg\/mL against several CRE and CRAB strains), highlighting the potential of <jats:italic>C<\/jats:italic>-glycosylation for an improved bioactive profile. This study is the first to show the potential of IM-targeting carbohydrate-based compounds for the treatment of infections caused by MDR Gram-negative pathogens of clinical importance.<\/jats:p>","DOI":"10.1038\/s41598-024-51428-6","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T09:02:43Z","timestamp":1706259763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alkyl deoxyglycoside-polymyxin combinations against critical priority carbapenem-resistant gram-negative bacteria"],"prefix":"10.1038","volume":"14","author":[{"given":"Ana M.","family":"de Matos","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia","family":"Calado","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Am\u00e9lia P.","family":"Rauter","sequence":"additional","affiliation":[]},{"given":"M. Concei\u00e7\u00e3o","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Manageiro","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Cani\u00e7a","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"51428_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jiph.2023.02.021","volume":"16","author":"SA Rehman","year":"2023","unstructured":"Rehman, S. A. A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemic. J. Infect. Public Health. 16, 611\u2013617 (2023).","journal-title":"J. Infect. Public Health."},{"key":"51428_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray, C. J. L. et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet. 399, 629\u2013655 (2022).","journal-title":"The Lancet."},{"key":"51428_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00181-19","volume":"22","author":"DMP De Oliveira","year":"2022","unstructured":"De Oliveira, D. M. P. et al. Antimicrobial resistance in ESKAPE pathogens. Clin. Microbiol. Rev. 22, e00181. https:\/\/doi.org\/10.1128\/CMR.00181-19 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"51428_CR4","unstructured":"World Health Organization. Antibacterial agents in clinical and preclinical development: An overview and analysis. https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2021.01 (2022)."},{"key":"51428_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.202200919","volume":"26","author":"AM de Matos","year":"2023","unstructured":"de Matos, A. M. Recent advances in the development and synthesis of carbohydrate-based molecules with promising antibacterial activity. Eur. J. Org. Chem. 26, e202200919. https:\/\/doi.org\/10.1002\/ejoc.202200919 (2023).","journal-title":"Eur. J. Org. Chem."},{"key":"51428_CR6","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1038\/s41467-018-06488-4","volume":"9","author":"C Dias","year":"2018","unstructured":"Dias, C. et al. Sugar-based bactericides targeting phosphatidylethanolamine-enriched membranes. Nat. Commun. 9, 4857 (2018).","journal-title":"Nat. Commun."},{"key":"51428_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbamem.2008.08.023","volume":"1788","author":"RM Epand","year":"2009","unstructured":"Epand, R. M. & Epand, R. F. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim. Biophys. Acta. 1788, 289\u2013294 (2009).","journal-title":"Biochim. Biophys. Acta."},{"key":"51428_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-021-00638-0","volume":"20","author":"J Sun","year":"2022","unstructured":"Sun, J., Rutherford, S. T., Silhavy, T. J. & Huang, K. C. Physical properties of the bacterial outer membrane. Nat. Rev. Microbiol. 20, 236\u2013248 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"51428_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00077-17","volume":"31","author":"R Domalon","year":"2018","unstructured":"Domalon, R., Idowu, T., Zhanel, G. G. & Schweizer, F. Antibiotic hybrids: the next generation of agents and adjuvants against Gram-negative pathogens?. Clin. Microbiol. Rev. 31, e00077. https:\/\/doi.org\/10.1128\/CMR.00077-17 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"51428_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/nyas.14280","volume":"1459","author":"CR MacNair","year":"2020","unstructured":"MacNair, C. R., Tsai, C. N. & Brown, E. D. Creative targeting of the Gram-negative outer membrane in antibiotic discovery. Ann. N. Y. Acad. Sci. 1459, 69\u201385 (2020).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"51428_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/membranes10080181","volume":"10","author":"CA Moubareck","year":"2020","unstructured":"Moubareck, C. A. Polymyxins and bacterial membranes: A review of antibacterial activity and mechanisms of resistance. Membranes. 10, 181 (2020).","journal-title":"Membranes."},{"key":"51428_CR12","unstructured":"European Medicines Agency. Assessment Report on Polymyxin-based products (EMA\/CHMP\/153652\/2015). https:\/\/www.ema.europa.eu\/en\/documents\/referral\/polymyxin-article-31-referral-assessment-report_en.pdf (2015)."},{"key":"51428_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/jac\/dkh369","volume":"54","author":"ME Sobieszczyk","year":"2004","unstructured":"Sobieszczyk, M. E. et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54, 566\u2013569 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"51428_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.csbj.2020.08.008","volume":"18","author":"M Hussein","year":"2020","unstructured":"Hussein, M. et al. Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multidrug-resistance of Gram-negative pathogens. Comput. Struct. Biotechnol. J. 18, 2247\u20132258 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"51428_CR15","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1021\/acsinfecdis.9b00159","volume":"6","author":"S French","year":"2020","unstructured":"French, S. et al. Potentiation of antibiotics against Gram-negative bacteria by polymyxin B analogue SPR741 from unique perturbation of the outer membrane. ACS Infect. Dis. 6, 1405\u20131412 (2020).","journal-title":"ACS Infect. Dis."},{"key":"51428_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim, L. M. et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 30, 1279\u20131291 (2010).","journal-title":"Pharmacotherapy."},{"key":"51428_CR17","doi-asserted-by":"crossref","unstructured":"Perez, F., et al. Polymyxins: To Combine or Not to Combine? Antibiotics (Basel). 8, 38. (2019).","DOI":"10.3390\/antibiotics8020038"},{"key":"51428_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng, W. et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145\u20131149 (2008).","journal-title":"J. Med. Chem."},{"key":"51428_CR19","doi-asserted-by":"publisher","first-page":"11707","DOI":"10.1021\/acs.jmedchem.0c00856","volume":"63","author":"J Meiers","year":"2020","unstructured":"Meiers, J. et al. Directing drugs to bugs: Antibiotic-carbohydrates targeting biofilm-associated lectins of Pseudomonas aeruginosa. J. Med. Chem. 63, 11707\u201311724 (2020).","journal-title":"J. Med. Chem."},{"key":"51428_CR20","doi-asserted-by":"publisher","first-page":"9201","DOI":"10.1021\/acs.jmedchem.9b01120","volume":"62","author":"R Sommer","year":"2019","unstructured":"Sommer, R. et al. Anti-biofilm agents against Pseudomonas aeruginosa: A structure-activity relationship study of C-glycosidic LecB inhibitors. J. Med. Chem. 62, 9201\u20139216 (2019).","journal-title":"J. Med. Chem."},{"key":"51428_CR21","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1002\/ejoc.201801764","volume":"12","author":"C Dias","year":"2019","unstructured":"Dias, C. et al. Assessing the optimal deoxygenation pattern of dodecyl glycosides for antimicrobial activity against Bacillus anthracis. Eur. J. Org. Chem. 12, 2224\u20132233 (2019).","journal-title":"Eur. J. Org. Chem."},{"key":"51428_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1039\/p19820000681","volume":"681","author":"PJ Garegg","year":"1982","unstructured":"Garegg, P. J., Johansson, R., Ortega, C. & Samuelsson, B. Novel reagent system for converting a hydroxy-group into an iodogroup in carbohydrates with inversion of configuration. Part 3. J. Chem. Soc. Perkin Trans. 681, 681\u2013683 (1982).","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"51428_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0008-6215(93)80074-O","volume":"245","author":"H-P Wessel","year":"1993","unstructured":"Wessel, H.-P., Viaud, M.-C. & Gardon, V. Preparation of 4,6-cyclo-hexopyranoses by palladium-mediated intramolecular cyclodehalogenation. Carbohydr. Res. 245, 233\u2013244 (1993).","journal-title":"Carbohydr. Res."},{"key":"51428_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/bip.22095","volume":"98","author":"MM Domingues","year":"2012","unstructured":"Domingues, M. M. et al. Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane model systems. Biopolymers. 98, 338\u2013344 (2012).","journal-title":"Biopolymers."},{"key":"51428_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/1753425913493337","volume":"20","author":"T Velkov","year":"2014","unstructured":"Velkov, T. et al. Surface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniae. Innate Immun. 20, 350\u2013363 (2014).","journal-title":"Innate Immun."},{"key":"51428_CR26","doi-asserted-by":"publisher","first-page":"17828","DOI":"10.1021\/acsomega.8b02260","volume":"3","author":"NK Khadka","year":"2018","unstructured":"Khadka, N. K., Aryal, C. M. & Pan, J. Lipopolysaccharide-dependent membrane permeation and lipid clustering caused by cyclic lipopeptide colistin. ACS Omega. 3, 17828\u201317834 (2018).","journal-title":"ACS Omega."},{"key":"51428_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009119","volume":"16","author":"JL Dombach","year":"2020","unstructured":"Dombach, J. L. et al. A small molecule that mitigates bacterial infection disrupts Gram-negative cell membranes and is inhibited by cholesterol and neutral lipids. PLoS Pathog. 16, e1009119. https:\/\/doi.org\/10.1371\/journal.ppat.1009119 (2020).","journal-title":"PLoS Pathog."},{"key":"51428_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jac\/dkn530","volume":"63","author":"N Aoki","year":"2009","unstructured":"Aoki, N. et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antibimicrob. Chemother. 63, 534\u2013542 (2009).","journal-title":"J. Antibimicrob. Chemother."},{"key":"51428_CR29","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1021\/acsinfecdis.1c00147","volume":"7","author":"EH Mood","year":"2021","unstructured":"Mood, E. H. et al. Antibiotic potentiation in multidrug-resistant Gram-negative pathogenic bacteria by a synthetic Peptidomimetic. ACS Infect. Dis. 7, 2152\u20132163 (2021).","journal-title":"ACS Infect. Dis."},{"key":"51428_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/nat.2012.0370","volume":"22","author":"A Ghosal","year":"2012","unstructured":"Ghosal, A. & Nielsen, P. E. Potent antibacterial antisense peptide-peptide nucleic acid conjugates against Pseudomonas aeruginosa. Nucleic Acid Ther. 22, 323\u2013334 (2012).","journal-title":"Nucleic Acid Ther."},{"key":"51428_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/antibiotics10050528","volume":"10","author":"Y Tao","year":"2021","unstructured":"Tao, Y. et al. Colistin treatment affects lipid composition of Acinetobacter baumannii. Antibiotics. 10, 528. https:\/\/doi.org\/10.3390\/antibiotics10050528 (2021).","journal-title":"Antibiotics."},{"key":"51428_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fmicb.2019.00331","volume":"10","author":"A Vermassen","year":"2019","unstructured":"Vermassen, A. et al. Cell wall hydrolases in bacteria: Insight on the diversity of cell wall amidases, glycosidases and peptidases toward peptidoglycan. Front. Microbiol. 10, 331. https:\/\/doi.org\/10.3389\/fmicb.2019.00331 (2019).","journal-title":"Front. Microbiol."},{"key":"51428_CR33","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1074\/jbc.REV119.010155","volume":"295","author":"T Do","year":"2020","unstructured":"Do, T., Page, J. E. & Walker, S. Uncovering the activities, biological roles, and regulation of bacterial cell wall hydrolases and tailoring enzymes. J. Biol. Chem. 295, 3347\u20133361 (2020).","journal-title":"J. Biol. Chem."},{"key":"51428_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fmicb.2019.00500","volume":"10","author":"O Irazoki","year":"2019","unstructured":"Irazoki, O., Hernandez, S. B. & Cava, F. Peptidoglycan muropeptides: Release, perception, and functions as signaling molecules. Front. Microbiol. 10, 500. https:\/\/doi.org\/10.3389\/fmicb.2019.00500 (2019).","journal-title":"Front. Microbiol."},{"key":"51428_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4266\/kjccm.2016.00731","volume":"32","author":"JY Lee","year":"2017","unstructured":"Lee, J. Y. et al. Outbreak of imipenemase-1-producing carbapenem-resistant Klebsiella pneumoniae in an intensive care unit. Korean J. Crit. Care Med. 32, 29\u201338 (2017).","journal-title":"Korean J. Crit. Care Med."},{"key":"51428_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcimb.2018.00004","volume":"8","author":"RM Martin","year":"2018","unstructured":"Martin, R. M. & Bachman, M. A. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front. Cell Infect. Microbiol. 8, 4. https:\/\/doi.org\/10.3389\/fcimb.2018.00004 (2018).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"51428_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3201\/eid2305.162034","volume":"23","author":"BM Wilson","year":"2017","unstructured":"Wilson, B. M. et al. Carbapenem-resistant Enterobacter cloacae in patients from the US veterans health administration, 2006\u20132015. Emerg. Infect. Dis. 23, 878\u2013880 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"51428_CR38","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1128\/AAC.05065-14","volume":"59","author":"V Manageiro","year":"2015","unstructured":"Manageiro, V. et al. Predominance of KPC-3 in a Survey for Carbapenemase-Producing Enterobacteriaceae in Portugal. Antimicrob. Agents Chemother. 59, 3588\u20133592 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"51428_CR39","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.2147\/IDR.S367588","volume":"15","author":"X Liang","year":"2022","unstructured":"Liang, X. et al. Outcomes and risk factors of bloodstream infections caused by carbapenem-resistant and non-carbapenem-resistant Klebsiella pneumoniae in China. Infect. Drug Resist. 15, 3161\u20133171 (2022).","journal-title":"Infect. Drug Resist."},{"key":"51428_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13756-022-01204-w","volume":"11","author":"K Chen","year":"2022","unstructured":"Chen, K. et al. Risk factors and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary-care hospital in China: an eight-year retrospective study. Antimicrob. Resist. Infect. Control. 11, 161. https:\/\/doi.org\/10.1186\/s13756-022-01204-w (2022).","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"51428_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1186\/s12879-021-06250-0","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Carbapenem-resistant Enterobacter cloacae complex in a tertiary hospital in Northeast China, 2010\u20132019. BMC Infect. Dis. 21, 611. https:\/\/doi.org\/10.1186\/s12879-021-06250-0 (2021).","journal-title":"BMC Infect. Dis."},{"key":"51428_CR42","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.2147\/IDR.S327595","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Molecular mechanisms and epidemiology of carbapenem-resistant Enterobacter cloacae complex isolated from Chinese patients during 2004\u20132018. Infect. Drug Resist. 14, 3647\u20133658 (2021).","journal-title":"Infect. Drug Resist."},{"key":"51428_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IDR.S234678","volume":"13","author":"X Tian","year":"2020","unstructured":"Tian, X. et al. Carbapenem-resistant Enterobacter cloacae causing nosocomial infections in southwestern China: Molecular epidemiology, risk factors, and predictors of mortality. Infect. Drug Resist. 13, 129\u2013137 (2020).","journal-title":"Infect. Drug Resist."},{"key":"51428_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fmicb.2017.00094","volume":"8","author":"Z Shi","year":"2017","unstructured":"Shi, Z., Zhao, H., Li, G. & Jia, W. Molecular characteristics of carbapenem-resistant Enterobacter cloacae in Ningxia Province, China. Front. Microbiol. 8, 94. https:\/\/doi.org\/10.3389\/fmicb.2017.00094 (2017).","journal-title":"Front. Microbiol."},{"key":"51428_CR45","unstructured":"Pfizer, Inc. Phase 3 studies of Pfizer\u2019s novel antibiotic combination offer new treatment hope for patients with multidrug-resistant infections and limited treatment options. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/phase-3-studies-pfizers-novel-antibiotic-combination-offer (2023)."},{"key":"51428_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106882","volume":"62","author":"M Kollef","year":"2023","unstructured":"Kollef, M. et al. The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence. Int. J. Antimicrob. Agents. 62, 106882. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106882 (2023).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"51428_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/membranes10080181","volume":"10","author":"CA Moubareck","year":"2020","unstructured":"Moubareck, C. A. Polymyxins and bacterial membranes: A review of antibacterial activity and mechanisms of resistance. Membranes. 10, 181. https:\/\/doi.org\/10.3390\/membranes10080181 (2020).","journal-title":"Membranes."},{"key":"51428_CR48","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/acs.jcim.7b00271","volume":"57","author":"DES Santos","year":"2017","unstructured":"Santos, D. E. S., Pol-Fachin, L., Lins, R. D. & Soares, T. A. Polymyxin binding to the bacterial outer membrane reveals cation displacement and increasing membrane curvature in susceptible but not resistant lipopolysaccharide chemotypes. J. Chem. Inf. Model. 57, 2181\u20132193 (2017).","journal-title":"J. Chem. Inf. Model."},{"key":"51428_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/bios12040196","volume":"12","author":"D Lavogina","year":"2022","unstructured":"Lavogina, D. et al. Revisiting the resazurin-based sensing of cellular viability: Widening the application horizon. Biosensors. 12, 196 (2022).","journal-title":"Biosensors."},{"key":"51428_CR50","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3389\/fmicb.2018.02864","volume":"9","author":"M Jangra","year":"2018","unstructured":"Jangra, M. et al. Purification, characterization and in vitro evaluation of polymyxin A from Paenibacillus dendritiformis: An unexplored member of the polymyxin family. Front. Microbiol. 9, 2864. https:\/\/doi.org\/10.3389\/fmicb.2018.02864 (2018).","journal-title":"Front. Microbiol."},{"key":"51428_CR51","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1128\/AAC.00280-12","volume":"56","author":"K Abdelarouf","year":"2012","unstructured":"Abdelarouf, K. et al. Characterization of polymyxin B-induced nephrotoxicity: Implications for dosing regimen design. Antimicrob. Agents Chemother. 56, 4625\u20134629 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"51428_CR52","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1021\/acs.jmedchem.5b01593","volume":"59","author":"A Gallardo-Godoy","year":"2016","unstructured":"Gallardo-Godoy, A. et al. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. J. Med. Chem. 59, 1068\u20131077 (2016).","journal-title":"J. Med. Chem."},{"key":"51428_CR53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12879-023-08339-0","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB. BMC Infect. Dis. 23, 351. https:\/\/doi.org\/10.1186\/s12879-023-08339-0 (2023).","journal-title":"BMC Infect. Dis."},{"key":"51428_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd3801","volume":"11","author":"PY Muller","year":"2012","unstructured":"Muller, P. Y. & Milton, M. N. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751\u2013761 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"51428_CR55","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.3390\/ijms232012457","volume":"23","author":"A Troudi","year":"2022","unstructured":"Troudi, A., Bolla, J. M., Klibi, N. & Brunel, J. M. An original and efficient antibiotic adjuvant strategy to enhance the activity of macrolide antibiotics against Gram-negative resistant strains. Int. J. Mol. Sci. 23, 12457. https:\/\/doi.org\/10.3390\/ijms232012457 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"51428_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/jac\/dkac445","volume":"78","author":"SY Kim","year":"2023","unstructured":"Kim, S. Y. et al. Exploitation of a novel adjuvant for polymyxin B against multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 78, 923\u2013932 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"51428_CR57","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1021\/ed083p782","volume":"83","author":"AV Demchenko","year":"2006","unstructured":"Demchenko, A. V., Pornsuriyasak, P. & De Meo, C. Acetal protecting groups in the organic laboratory: Synthesis of methyl 4,6-O-benzylidene-\u03b1-D-glucopyranoside. J. Chem. Educ. 83, 782\u2013784 (2006).","journal-title":"J. Chem. Educ."},{"key":"51428_CR58","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0008-6215(88)80072-7","volume":"180","author":"D Beaupere","year":"1988","unstructured":"Beaupere, D., Boutbaiba, I., Menailly, G. & Uzan, R. D\u00e9protection s\u00e9lective par transfert d\u2019hydrog\u00e8ne, du groupe OH-2 dans le m\u00e9thyl-2,3-di-O-benzyl-4,6-O-benzylid\u00e8ne-\u03b1-D-glucopyranoside. Carbohydr. Res. 180, 152\u2013155 (1988).","journal-title":"Carbohydr. Res."},{"key":"51428_CR59","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ejoc.201201520","volume":"2013","author":"A Martins","year":"2013","unstructured":"Martins, A. et al. Tuning the bioactivity of tensioactive deoxy glycosides to structure: Antibacterial activity versus selective cholinesterase inhibition rationalized by molecular docking. Eur. J. Org. Chem. 2013, 1448\u20131459 (2013).","journal-title":"Eur. J. Org. Chem."},{"key":"51428_CR60","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/acs.jnatprod.5b00370","volume":"78","author":"AM de Matos","year":"2015","unstructured":"de Matos, A. M. et al. Epoxylathyrol derivatives: Modulation of ABCB1-mediated multidrug resistance in human colon adenocarcinoma and mouse T-lymphoma cells. J. Nat. Prod. 78, 2215\u20132228 (2015).","journal-title":"J. Nat. Prod."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51428-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T09:04:42Z","timestamp":1706259882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51428"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51428-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2219"}}